NASDAQ:MNOV

MediciNova Competitors

$4.63
+0.08 (+1.76 %)
(As of 04/14/2021 12:25 PM ET)
Add
Compare
Today's Range
$4.47
Now: $4.63
$4.70
50-Day Range
$4.56
MA: $5.48
$8.74
52-Week Range
$4.43
Now: $4.63
$13.25
Volume2,989 shs
Average Volume841,496 shs
Market Capitalization$225.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4

Competitors

MediciNova (NASDAQ:MNOV) Vs. ANNX, AFMD, DYN, MRUS, BTAI, and EPZM

Should you be buying MNOV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MediciNova, including Annexon (ANNX), Affimed (AFMD), Dyne Therapeutics (DYN), Merus (MRUS), BioXcel Therapeutics (BTAI), and Epizyme (EPZM).

MediciNova (NASDAQ:MNOV) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares MediciNova and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediciNovaN/A-17.56%-16.62%
AnnexonN/A-566.22%-32.99%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MediciNova and Annexon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediciNova00203.00
Annexon00503.00

MediciNova currently has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Annexon has a consensus price target of $34.3333, suggesting a potential upside of 44.02%. Given MediciNova's higher possible upside, equities research analysts clearly believe MediciNova is more favorable than Annexon.

Earnings and Valuation

This table compares MediciNova and Annexon's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNovaN/AN/A$-12,940,000.00N/AN/A
AnnexonN/AN/A$-37,180,000.00N/AN/A

Institutional & Insider Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 91.2% of Annexon shares are owned by institutional investors. 16.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MediciNova beats Annexon on 5 of the 7 factors compared between the two stocks.

Affimed (NASDAQ:AFMD) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Valuation & Earnings

This table compares Affimed and MediciNova's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Affimed$23.96 million38.97$-36,250,000.00($0.56)-18.88
MediciNovaN/AN/A$-12,940,000.00N/AN/A

MediciNova has lower revenue, but higher earnings than Affimed.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Affimed and MediciNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affimed00503.00
MediciNova00203.00

Affimed currently has a consensus price target of $13.80, indicating a potential upside of 34.37%. MediciNova has a consensus price target of $13.00, indicating a potential upside of 180.78%. Given MediciNova's higher possible upside, analysts plainly believe MediciNova is more favorable than Affimed.

Profitability

This table compares Affimed and MediciNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Affimed-172.01%-99.24%-37.40%
MediciNovaN/A-17.56%-16.62%

Insider & Institutional Ownership

52.3% of Affimed shares are held by institutional investors. Comparatively, 21.7% of MediciNova shares are held by institutional investors. 16.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Affimed has a beta of 2.81, meaning that its share price is 181% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Summary

MediciNova beats Affimed on 6 of the 10 factors compared between the two stocks.

MediciNova (NASDAQ:MNOV) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Insider and Institutional Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are owned by institutional investors. 16.0% of MediciNova shares are owned by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares MediciNova and Dyne Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNovaN/AN/A$-12,940,000.00N/AN/A
Dyne TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares MediciNova and Dyne Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediciNovaN/A-17.56%-16.62%
Dyne TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MediciNova and Dyne Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediciNova00203.00
Dyne Therapeutics00503.00

MediciNova presently has a consensus target price of $13.00, suggesting a potential upside of 180.78%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 95.38%. Given MediciNova's higher probable upside, research analysts plainly believe MediciNova is more favorable than Dyne Therapeutics.

Summary

Dyne Therapeutics beats MediciNova on 4 of the 6 factors compared between the two stocks.

MediciNova (NASDAQ:MNOV) and Merus (NASDAQ:MRUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares MediciNova and Merus' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNovaN/AN/A$-12,940,000.00N/AN/A
Merus$31.13 million28.35$-55,150,000.00($2.33)-9.94

MediciNova has higher earnings, but lower revenue than Merus.

Insider and Institutional Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 62.6% of Merus shares are owned by institutional investors. 16.0% of MediciNova shares are owned by company insiders. Comparatively, 7.4% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MediciNova and Merus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediciNovaN/A-17.56%-16.62%
Merus-295.98%-78.70%-36.12%

Analyst Recommendations

This is a summary of recent recommendations for MediciNova and Merus, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediciNova00203.00
Merus01402.80

MediciNova presently has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Merus has a consensus price target of $27.80, suggesting a potential upside of 17.80%. Given MediciNova's stronger consensus rating and higher probable upside, equities analysts plainly believe MediciNova is more favorable than Merus.

Volatility & Risk

MediciNova has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Merus has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

MediciNova beats Merus on 8 of the 11 factors compared between the two stocks.

BioXcel Therapeutics (NASDAQ:BTAI) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for BioXcel Therapeutics and MediciNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioXcel Therapeutics001103.00
MediciNova00203.00

BioXcel Therapeutics presently has a consensus price target of $101.8182, suggesting a potential upside of 183.30%. MediciNova has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Given BioXcel Therapeutics' higher probable upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than MediciNova.

Profitability

This table compares BioXcel Therapeutics and MediciNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioXcel TherapeuticsN/A-74.22%-64.31%
MediciNovaN/A-17.56%-16.62%

Insider & Institutional Ownership

48.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 21.7% of MediciNova shares are held by institutional investors. 9.4% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 16.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

BioXcel Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Valuation and Earnings

This table compares BioXcel Therapeutics and MediciNova's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.85
MediciNovaN/AN/A$-12,940,000.00N/AN/A

Summary

MediciNova beats BioXcel Therapeutics on 5 of the 8 factors compared between the two stocks.

MediciNova (NASDAQ:MNOV) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Insider and Institutional Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 89.8% of Epizyme shares are owned by institutional investors. 16.0% of MediciNova shares are owned by company insiders. Comparatively, 16.3% of Epizyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MediciNova and Epizyme's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNovaN/AN/A$-12,940,000.00N/AN/A
Epizyme$23.80 million35.84$-170,290,000.00($1.93)-4.34

MediciNova has higher earnings, but lower revenue than Epizyme.

Analyst Recommendations

This is a breakdown of current ratings and price targets for MediciNova and Epizyme, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediciNova00203.00
Epizyme04302.43

MediciNova currently has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Epizyme has a consensus price target of $17.00, suggesting a potential upside of 102.62%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than Epizyme.

Profitability

This table compares MediciNova and Epizyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediciNovaN/A-17.56%-16.62%
Epizyme-1,899.35%-83.45%-52.66%

Risk & Volatility

MediciNova has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Summary

MediciNova beats Epizyme on 6 of the 11 factors compared between the two stocks.


MediciNova Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Annexon logo
ANNX
Annexon
1.9$23.83+3.3%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.57+6.4%$873.54 million$23.96 million-17.92Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.46+3.2%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.15+2.2%$863.20 million$31.13 million-7.54Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$36.05+4.5%$845.56 millionN/A-10.70
Epizyme logo
EPZM
Epizyme
1.8$8.38+2.3%$833.11 million$23.80 million-3.76
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.50+1.0%$822.01 million$322.36 million125.00
Humanigen logo
HGEN
Humanigen
1.7$15.49+1.8%$813.46 millionN/A0.00Analyst Report
Increase in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.13+5.1%$806.52 million$296.70 million49.24Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.57+4.4%$758.12 million$40.89 million-3.64Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.36+3.0%$750.64 million$322.07 million-5.10Decrease in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.35+4.2%$732.39 million$148.36 million-7.10News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.55+4.8%$727.39 million$150,000.00-5.07
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.93+2.7%$723.91 million$2.22 million-17.24
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.56+8.5%$723.63 millionN/A0.00Increase in Short Interest
Chimerix logo
CMRX
Chimerix
1.3$8.44+1.5%$711.99 million$12.52 million-14.81Analyst Report
Increase in Short Interest
Ardelyx logo
ARDX
Ardelyx
1.6$8.05+10.6%$710.50 million$5.28 million-7.97Unusual Options Activity
Veru logo
VERU
Veru
1.4$10.14+3.1%$706.90 million$42.59 million-36.21Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.10+4.2%$698.95 million$252 million-2.26News Coverage
OrganiGram logo
OGI
OrganiGram
1.6$2.68+8.6%$677.07 million$64.61 million-3.94Earnings Announcement
Analyst Report
Decrease in Short Interest
News Coverage
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$30.25+3.1%$676.77 million$13.80 million-14.61Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.00+1.0%$667.23 million$19.56 million-19.42
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$12.04+3.4%$664.02 millionN/A-4.84Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.73+0.9%$653.32 millionN/A-2.45Increase in Short Interest
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.58+7.5%$648.86 million$6.83 million-20.19Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.39+3.9%$641.81 million$143.01 million-1.22
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$25.38+3.0%$635.65 million$12.69 million-12.20Increase in Short Interest
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.98+1.2%$622.54 million$9.64 million-5.37News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.91+7.4%$621.98 million$5.09 million-6.52Analyst Downgrade
News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.75+3.7%$614.14 million$59.29 million-25.00Increase in Short Interest
News Coverage
Gap Up
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$36.99+2.8%$602.22 millionN/A-17.13
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.99+0.6%$589.46 million$17.26 million-3.89Analyst Revision
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.73+3.3%$584.23 millionN/A-9.96Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.52+4.7%$561.28 million$8 million-7.94
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$43.64+3.5%$556.83 million$195.89 million124.69
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.77+4.1%$547.56 millionN/A-5.46Gap Down
Inventiva logo
IVA
Inventiva
0.0$13.75+1.7%$540.43 millionN/A0.00News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.98+0.7%$539.54 million$26.74 million17.45
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.92+4.7%$536.73 millionN/A-9.24Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.62+3.6%$529.13 million$1.19 million-6.92
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.11+5.6%$520.28 millionN/A-4.85
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.15+4.0%$519.55 millionN/A-5.72
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.12+6.3%$517.94 millionN/A-4.36
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.42+1.7%$516.80 million$25 million-19.11Analyst Report
Evolus logo
EOLS
Evolus
1.3$12.08+3.5%$509.93 million$34.92 million-5.95Analyst Report
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.3$8.83+3.3%$499.29 million$59.22 million44.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.24+0.4%$494.53 million$49.65 million-1.74Analyst Upgrade
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.72+0.9%$492.23 million$58.12 million-15.95Decrease in Short Interest
Provention Bio logo
PRVB
Provention Bio
1.6$8.41+7.7%$491.79 millionN/A-5.64Analyst Report
Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.